Citius Oncology (CTOR) Free Cash Flow (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Free Cash Flow data on file, last reported at -$3.8 million in Q1 2026.

• On a quarterly basis, Free Cash Flow changed N/A year-over-year to -$3.8 million in Q1 2026; TTM through Mar 2026 was -$11.2 million, a 2955.55% decrease from a year earlier, with the FY2025 full-year figure at -$5.5 million, down 4446.59% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$3.8 million, up from -$7.4 million in the prior quarter.
• Over the last five years, Free Cash Flow for CTOR reached as high as -$100256.0 in Q2 2023 and fell as low as -$7.4 million in Q4 2025.
• Historically, Free Cash Flow has averaged -$1.8 million across 4 years, with a median of -$366106.0 in 2024.
• On a YoY basis, Free Cash Flow climbed as much as 13.56% in 2024 and fell as far as 265.17% in 2024.
• Year by year, Free Cash Flow stood at -$382527.0 in 2023, then rose by 4.29% to -$366106.0 in 2024, then plunged by 1908.97% to -$7.4 million in 2025, then surged by 47.9% to -$3.8 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$3.8 million in Q1 2026, -$7.4 million in Q4 2025, and -$366106.0 in Q2 2024.